Prognostic modeling of early-onset nondistal gastric cancer identifies ARSB–PDCD1 ratio as an immune-related survival stratifier
This study developed a clinical prognostic model for EONDGC and therefore identified <i>ARSB</i> and <i>PDCD1</i> as key molecular markers. The APR value enhances survival stratification, offering valuable insights into personalized prognosis and potential immunotherapy strategies.
Authors
- Yulong He
- Huaixiang Zhou
- Youheng Jiang
- Kaiming Wu
- Caiyan An (ORCID: https://orcid.org/0000-0002-0820-3350)
- Xin Zhong (ORCID: https://orcid.org/0009-0008-0596-6425)
- Zhou Chen (ORCID: https://orcid.org/0000-0001-5398-4654)
- Junjing Zhang (ORCID: https://orcid.org/0000-0002-1274-1098)
- Zhiqiang Zhang (ORCID: https://orcid.org/0000-0001-7698-7655)
- Ningning Li (ORCID: https://orcid.org/0000-0002-0414-5878)
- Yuan‐Han Yang (ORCID: https://orcid.org/0000-0002-1918-9021)
- Qunlong Jin (ORCID: https://orcid.org/0009-0006-8889-6666)
- Fu Zhang (ORCID: https://orcid.org/0000-0002-3479-6962)
Institutions
- Sun Yat-sen University (CN)
- The Seventh Affiliated Hospital of Sun Yat-sen University (CN)
- Hohhot First Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-09-29
- DOI
- https://doi.org/10.3389/fimmu.2025.1655106
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00